The study of cisplatin and vinorelbine in metastatic uterine cervical cancer

• Main Authors: Kamnerdsupaphon P., Chitapanarux I., Tharavichitkul E., Sukthomya V., Lorvidhaya V.
• Format: Article
• Language: English
• Published: 2014
• Online Access: http://www.scopus.com/inward/record.url?eid=2-s2.0-67650430009&partnerID=40&md5=5591efb448d501a961ee2efd000d530d; http://www.ncbi.nlm.nih.gov/pubmed/19530590; http://cmuir.cmu.ac.th/handle/6653943832/2850
• Institution: Chiang Mai University

Objective: To determine the therapeutic efficacy of cisplatin in combination with vinorelbine in the treatment of patients with metastatic cervical cancer. Material and Method: a total of 17 patients were enrolled in the present study. The median age was 46 years (38-65). There were 6 patients who were diagnosed as stage IVB cervical cancer without previous treatment. The patients were planned to receive cisplatin 80 mg/m2 on day 1 and vinorelbine at 30 mg/m2 on day 1 and 8 every 3 weeks. Results: Fifteen patients were available for evaluation: 2 (13.3%) achieved a complete response, 8 (53.4%) partial responses, 3 (20%) stable diseases and 2 (13.3%) progression of the disease. Myelosuppression was the major toxicity. Grade 3-4 toxicities include 66.7% hemoglobin and 26.7% neutropenia. No other significant side effects were found. Conclusion: Cisplatin-vinorelbine is an active and well-tolerated regimen in metastatic cervical carcinoma. These results require confirmation.